NCT05731843

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

A Phase 1, Open-Label Study to Evaluate the Potential Drug-Drug Interaction Between Bemnifosbuvir and Ruzasvir and Food-Drug Interaction in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Drug-drug interaction study of Ruzasvir and Bemnifosbuvir

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	Cohort 1 BEM + Ruzasvir	Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
DRUG	Cohort 2 Ruzasvir + BEM	Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions

Timeline

• Start date: 2023-01-30
• Primary completion: 2023-03-15
• Completion: 2023-03-15
• First posted: 2023-02-16
• Last updated: 2023-06-01

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study